🎯 3 free searches remaining
Microbix Biosystems Inc. develops proprietary biological solutions for human health. The company shows strengths in liquidity with a current ratio of 8.48 and a manageable debt/equity ratio of 0.16, indicating solid financial stability. However, concerns arise from its negative net margin of -12.1% and low EBITDA margin of 0.4%, suggesting profitability challenges. Despite a healthy gross margin of 53.0%, the low market valuation of $0.22 may reflect investor skepticism regarding its ability to convert revenue into profit effectively.
Loading financial metrics...
Revenue fell 26.8% year-over-year from $25.4M to $18.6M. The decline has persisted for multiple quarters.
Company posted a loss of $-2.2M over the last year, representing 12.1% of revenue.
Gross profit margin decreased from 60.6% to 53.0% compared to last year.
Strong gross margin of 53.0% reflects healthy unit economics.
Fortress balance sheet with cash exceeding debt by 171%, providing significant financial flexibility.
Excellent liquidity with current ratio of 8.5x ensures operational stability.
Low debt-to-revenue ratio of 24.1% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.